Hyperkalemia Management with Intravenous Insulin in Patients with Reduced Kidney Function

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Sep 14

PMID 39274318

Authors

Maram A Alzahrani

Numan A AlAbdan

Zainab S Alahmari

Nouf M Alshehri

Lama H Alotaibi

Omar A Almohammed

Affiliations

Soon will be listed here.

Abstract

: Insufficient kidney function increases the risk of hyperkalemia and hypoglycemia, particularly in hemodialysis-dependent patients. Hypoglycemia is a common complication of insulin-based hyperkalemia treatment. This study aims to evaluate the efficacy and safety of hyperkalemia treatment in hemodialysis-dependent and -non-dependent patients and identify risk factors associated with hypoglycemia. : A retrospective observational cohort study was conducted to assess the efficacy and safety of hyperkalemia treatment including patients with reduced kidney function and hyperkalemia treated with intravenous insulin. The decline rate of potassium and glucose levels were compared between hemodialysis-dependent and non-dependent patients. In addition, univariate and multivariable logistic regression analyses were performed to identify risk factors associated with hypoglycemia. : A total of 172 patients with hyperkalemia and reduced kidney function were included. The steepest reduction of serum potassium levels happened within the first 6 h after insulin administration, at 1.1 and 0.9 mmol/L for hemodialysis-dependent and non-dependent patients, respectively. The incidence of hypoglycemia was 18%, and no significant difference was found between cohorts. Hemodialysis-dependent patients were more likely to be readmitted within one month with hyperkalemia, while all-cause ICU admission was more likely for non-dependent patients. Older patients, and those who had heart failure or received a second dose of insulin to treat hyperkalemia, were more likely to experience hypoglycemia. : Monitoring blood glucose levels following insulin administration is essential given the complexity of patients' factors associated with hypoglycemia resulting from hyperkalemia treatment in patients with insufficient kidney function.

References

Tee S, Devine K, Potts A, Javaid U, Razvi S, Quinton R . Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia. Clin Endocrinol (Oxf). 2020; 94(2):176-182. DOI: 10.1111/cen.14343. View

Gianchandani R, Neupane S, Iyengar J, Heung M . PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW. Endocr Pract. 2016; 23(3):353-362. DOI: 10.4158/EP161471.RA. View

Humphrey T, Davids M, Chothia M, Pecoits-Filho R, Pollock C, James G . How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022; 15(4):727-737. PMC: 8967676. DOI: 10.1093/ckj/sfab243. View

Moussavi K, Fitter S, Gabrielson S, Koyfman A, Long B . Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician. J Emerg Med. 2019; 57(1):36-42. DOI: 10.1016/j.jemermed.2019.03.043. View

Palmer B . Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. Mayo Clin Proc. 2019; 95(2):339-354. DOI: 10.1016/j.mayocp.2019.05.019. View

Tran A, Rushakoff R, Prasad P, Murray S, Monash B, MacMaster H . Decreasing Hypoglycemia following Insulin Administration for Inpatient Hyperkalemia. J Hosp Med. 2020; 15:E1. DOI: 10.12788/jhm.3413. View

Beard M, McKenzie J, Potter T, Varney Gill K . Evaluating Risk Factors for Developing Hypoglycemia During Treatment of Hyperkalemia With Intravenous Regular Insulin. J Pharm Pract. 2024; 37(5):1091-1098. DOI: 10.1177/08971900231223025. View

Scott N, Klein L, Cales E, Driver B . Hypoglycemia as a complication of intravenous insulin to treat hyperkalemia in the emergency department. Am J Emerg Med. 2018; 37(2):209-213. DOI: 10.1016/j.ajem.2018.05.016. View

Alsahli M, Gerich J . Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc. 2014; 89(11):1564-71. DOI: 10.1016/j.mayocp.2014.07.013. View

10.

Abe M, Kalantar-Zadeh K . Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015; 11(5):302-13. PMC: 6015632. DOI: 10.1038/nrneph.2015.38. View

11.

Brueske B, Sidhu M, Schulman-Marcus J, Kashani K, Barsness G, Jentzer J . Hyperkalemia Is Associated With Increased Mortality Among Unselected Cardiac Intensive Care Unit Patients. J Am Heart Assoc. 2019; 8(7):e011814. PMC: 6509722. DOI: 10.1161/JAHA.118.011814. View

12.

Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J . Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x. View

13.

Li H, Tai P, Hwang Y, Lin S, Lan L . Causes of Hospitalization among End-Stage Kidney Disease Cohort before and after Hemodialysis. Int J Environ Res Public Health. 2022; 19(16). PMC: 9408097. DOI: 10.3390/ijerph191610253. View

14.

Hougen I, Leon S, Whitlock R, Rigatto C, Komenda P, Bohm C . Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective Cohort. Kidney Int Rep. 2021; 6(5):1309-1316. PMC: 8116905. DOI: 10.1016/j.ekir.2021.02.038. View

15.

Shrishrimal K, Hart P, Michota F . Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med. 2009; 76(11):649-55. DOI: 10.3949/ccjm.76a.09054. View

16.

Abe M, Kaizu K, Matsumoto K . Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial. 2007; 11(4):280-7. DOI: 10.1111/j.1744-9987.2007.00491.x. View

17.

Apel J, Reutrakul S, Baldwin D . Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease. Clin Kidney J. 2015; 7(3):248-50. PMC: 4377748. DOI: 10.1093/ckj/sfu026. View

18.

Kijprasert W, Tarudeeyathaworn N, Loketkrawee C, Pimpaporn T, Pattarasettaseranee P, Tangsuwanaruk T . Predicting hypoglycemia after treatment of hyperkalemia with insulin and glucose (Glu-K60 score). BMC Emerg Med. 2022; 22(1):179. PMC: 9652909. DOI: 10.1186/s12873-022-00748-9. View

19.

Khanagavi J, Gupta T, Aronow W, Shah T, Garg J, Ahn C . Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch Med Sci. 2014; 10(2):251-7. PMC: 4042045. DOI: 10.5114/aoms.2014.42577. View

20.

LaRue H, Peksa G, Shah S . A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency. Pharmacotherapy. 2017; 37(12):1516-1522. DOI: 10.1002/phar.2038. View